Literature DB >> 112637

Binding of imipramine to plasma protein and to brain tissue: relationship to CSF tricyclic levels in man.

W Z Potter, G Muscettola, F K Goodwin.   

Abstract

The possible clinical significance of the plasma protein binding of tricyclic antidepressants has been evaluated using imipramine (IMI), a typical tricyclic. Using equilibrium dialysis, the in vitro binding of IMI to plasma was compared to that of brain tissue. Cerebrospinal fluid (CSF) IMI was used as an independent measure of 'free' drug in the central nervous system. Intrinsic metabolic clearances were calculated on the basis of steady-state plasma IMI concentrations. There were three significant results: (1) variations in plasma binding are not great; (2) plasma protein binding does not limit the entry of IMI into the CSF; (3) variations in metabolism (intrinsic clearance) account for almost all variations in CSF concentrations of drug. It is concluded that measurement of free tricyclic antidepressant is not indicated in studies of clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 112637     DOI: 10.1007/bf00429700

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Simultaneous measurement of imipramine and desipramine by selected ion recording with deuterated internal standards.

Authors:  M Claeys; G Muscettola; S P Markey
Journal:  Biomed Mass Spectrom       Date:  1976-06

2.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

3.  Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique.

Authors:  F K Goodwin; R M Post; D L Dunner; E K Gordon
Journal:  Am J Psychiatry       Date:  1973-01       Impact factor: 18.112

4.  Theoretical changes in drug distribution resulting from changes in binding to plasma proteins and to tissues.

Authors:  S H Curry
Journal:  J Pharm Pharmacol       Date:  1970-10       Impact factor: 3.765

5.  Plasma binding of imipramine and clinical outcome.

Authors:  A H Glassman; M J Hurwic; J M Perel
Journal:  Am J Psychiatry       Date:  1973-12       Impact factor: 18.112

6.  Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.

Authors:  L Lund; A Berlin; K M Lunde
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

7.  A comparison of the binding of drugs to adult and cord plasma.

Authors:  A W Pruitt; P G Dayton
Journal:  Eur J Clin Pharmacol       Date:  1971-12       Impact factor: 2.953

8.  Plasma levels and antidepressive effect of imipramine.

Authors:  L F Gram; N Reisby; I Ibsen; A Nagy; S J Dencker; P Bech; G O Petersen; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

9.  Self-inhibiting action of nortriptylin's antidepressive effect at high plasma levels: a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression.

Authors:  P Kragh-Sorensen; C E Hansen; P C Baastrup; E F Hvidberg
Journal:  Psychopharmacologia       Date:  1976-02-02

10.  Clinical implications of imipramine plasma levels for depressive illness.

Authors:  A H Glassman; J M Perel; M Shostak; S J Kantor; J L Fleiss
Journal:  Arch Gen Psychiatry       Date:  1977-02
View more
  8 in total

Review 1.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 2.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 3.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of imipramine and desipramine.

Authors:  F R Sallee; B G Pollock
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 5.  Current antidepressant drugs: their clinical use.

Authors:  L E Hollister
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

6.  Binding of amitriptyline and nortriptyline in plasma determined from their equilibrium distributions between red cells and plasma, and between red cells and buffer solution.

Authors:  J E Burch; S G Roberts; M A Raddats
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Evaluation of the levels of free and total amitriptyline and metabolites in the plasma and brain of the rat after long-term administration of doses used in receptor studies.

Authors:  P Baumann; J M Gaillard; M Jonzier-Perey; C Gerber; C Bouras
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  A quantitative study in the rat on the relationship between imipramine levels in brain and serum.

Authors:  M van Wijk; J Korf
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.